secwatch.observer — SEC 8-K summary
======================================

Issuer:     Fulgent Genetics, Inc. (FLGT)
CIK:        0001674930
Form:       8-K
Filed at:   2023-01-03T23:59:59+00:00
Accession:  0000950170-23-000048
Event type: leadership
Sentiment:  positive
Materiality: 0.35
Item codes: 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fulgent Genetics appoints Reggie Groves to board, cures Nasdaq audit committee deficiency
--------------------------------------------------------------------------------

- Reggie Groves appointed to Fulgent Board effective Jan 3, 2023; serves on Audit, Compensation, and Nominating/Governance committees.
- Appointment resolves non-compliance with Nasdaq Rule 5605 requiring three independent directors on Audit Committee (disclosed Nov 18, 2022).
- Groves brings 13 years at Medtronic and experience as CFO/COO at Stimwave, CEO at REVA Medical, and board service at AtriCure.
- Groves will receive standard compensation per Non-Employee Director Compensation Policy and entered indemnification agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1674930/000095017023000048/0000950170-23-000048-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1674930/000095017023000048/flgt-20230103.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-000048

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer